Clinical Trial

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

Name: Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma — clinical trial record (NCT07497607)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: REDUCE-30

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a single-arm, phase II study that is designed to investigate nodal and primary tumor CTV dose de-escalation (30 Gy) in HPV positive oropharyngeal cancer.

Protocol Amendment History 2 changes

critical Recruitment opened 2026-05-19

critical Primary endpoint(s) modified 2026-05-19

Trial Details

NCT Number	NCT07497607
Lead Sponsor	Sara Medek
Conditions	Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Enrollment	31 participants
Start Date	2026-05-13
Primary Completion	2031-05-13 (estimated)
Study Completion	2036-05-13 (estimated)
Updated on ClinicalTrials.gov	2026-05-18